Quest Diagnostics Cash Flow from Investing Activities 2010-2023 | DGX

Quest Diagnostics annual/quarterly cash flow from investing activities history and growth rate from 2010 to 2023. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
  • Quest Diagnostics cash flow from investing activities for the quarter ending December 31, 2023 was $-1.061B, a 95.4% increase year-over-year.
  • Quest Diagnostics cash flow from investing activities for the twelve months ending December 31, 2023 was $-3.006B, a 125.68% increase year-over-year.
  • Quest Diagnostics annual cash flow from investing activities for 2023 was $-1.061B, a 95.4% increase from 2022.
  • Quest Diagnostics annual cash flow from investing activities for 2022 was $-0.543B, a 2685.71% decline from 2021.
  • Quest Diagnostics annual cash flow from investing activities for 2021 was $0.021B, a 102.72% decline from 2020.
Quest Diagnostics Annual Cash Flow Investing
(Millions of US $)
2023 $-1,061
2022 $-543
2021 $21
2020 $-772
2019 $-411
2018 $-801
2017 $-830
2016 $-127
2015 $-362
2014 $-1,025
2013 $328
2012 $-217
2011 $-1,243
2010 $-217
2009 $-196
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $15.460B $9.252B
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $17.436B 10.55
DaVita (DVA) United States $12.016B 14.93
Encompass Health (EHC) United States $8.745B 22.38
Chemed (CHE) United States $8.614B 26.70
Elanco Animal Health (ELAN) United States $8.436B 21.89
Option Care Health (OPCH) United States $5.209B 19.72
RadNet (RDNT) United States $4.191B 87.28
Amedisys (AMED) United States $3.128B 22.16
LifeStance Health (LFST) United States $2.825B 0.00
Astrana Health (ASTH) United States $2.242B 30.32
Addus HomeCare (ADUS) United States $1.798B 25.73
U.S Physical Therapy (USPH) United States $1.603B 42.90
Pennant (PNTG) United States $0.667B 35.25
Aveanna Healthcare Holdings (AVAH) United States $0.494B 0.00
Atai Life Sciences (ATAI) Germany $0.320B 0.00
Daxor (DXR) United States $0.045B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.027B 0.00
ATI Physical Therapy (ATIP) United States $0.022B 0.00
Psychemedics (PMD) United States $0.015B 0.00
Ontrak (OTRK) United States $0.014B 0.00
Novo Integrated Sciences (NVOS) United States $0.011B 0.00
IMAC Holdings (BACK) United States $0.004B 0.00